Khorrami Samaneh, Tavakoli Masoumeh, Safari Elahe
Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Iran J Pathol. 2019 Spring;14(2):104-112. doi: 10.30699/IJP.14.2.104. Epub 2019 Jun 10.
S100A8/A9 is a heterodimer calcium-binding protein which is involved in tumor cell proliferation, adhesion and invasion, and is proposed as a biomarker for better diagnosis and prognosis in many cancers. The aim of this study was to evaluate the simultaneous serum-based level of S100A8/A9 and CA15-3 as well-illustrated cancer biomarkers, as well as their prognostic value in breast cancer patients and healthy matched controls.
Thirty breast cancer patients at different stages of disease and healthy matched controls with no history of inflammatory, autoimmune diseases, or cancer, were enrolled in the study. The levels of S100A8/A9 and CA15-3 were assessed serologically using the Enzyme-linked immunosorbent assay (ELISA) method, and the relevance of these markers with patients' clinicopathological features were subsequently assessed.
Based on our data, the serum levels of both S100A8/A9 and CA15-3 were significantly higher in patients compared to the healthy controls, and thus positively correlated with tumor size. Also, statistical analysis shows that the serum level of S100A8/A9 has 100% specificity and sensitivity (AUC = 1.00, 95% CI) for the diagnosis of breast cancer patients.
According to our data as well as other observations, the S100A8/A9 heterodimer can be considered as a potential biomarker for the proper diagnosis and prognosis of breast cancer.
S100A8/A9是一种异二聚体钙结合蛋白，参与肿瘤细胞增殖、黏附和侵袭，在多种癌症中被提议作为更好诊断和预后的生物标志物。本研究旨在评估血清中S100A8/A9和CA15-3这两种已明确的癌症生物标志物的水平，以及它们在乳腺癌患者和健康对照者中的预后价值。
本研究纳入了30例处于不同疾病阶段的乳腺癌患者以及无炎症、自身免疫性疾病或癌症病史的健康对照者。采用酶联免疫吸附测定（ELISA）法血清学评估S100A8/A9和CA15-3的水平，随后评估这些标志物与患者临床病理特征的相关性。
根据我们的数据，与健康对照者相比，患者血清中S100A8/A9和CA15-3的水平均显著更高，因此与肿瘤大小呈正相关。此外，统计分析表明，S100A8/A9血清水平对乳腺癌患者诊断的特异性和敏感性均为100%（曲线下面积=1.00，95%置信区间）。
根据我们的数据以及其他观察结果，S100A8/A9异二聚体可被视为乳腺癌正确诊断和预后的潜在生物标志物。
